United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

These data were reported to the NYC DOHMH by March 31, 2021 This dataset includes data on new diagnoses of HIV and AIDS in NYC for the calendar years 2016 through 2020. Reported cases and case rates (per 100,000 population) are stratified by United Hospital Fund (UHF) neighborhood, sex, and race/ethnicity. Note: - Cells marked "NA" cannot be calculated because of cell suppression or 0 denominator.

United States US: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.110 Ratio in 2019. This stayed constant from the previous number of 0.110 Ratio for 2018. United States US: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.120 Ratio from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 0.130 Ratio in 2012 and a record low of 0.110 Ratio in 2019. United States US: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.020 % in 2014. This stayed constant from the previous number of 0.020 % for 2013. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.030 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.030 % in 2012 and a record low of 0.020 % in 2014. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;

This dataset contains surveillance data on diagnoses of HIV for the United States in estimates rates and numbers for Human Immunodeficiency Virus (HIV) infection diagnosis and stage 3 infection Acquired Immunodeficiency Syndrome (AIDS) as collected by the Centers for Disease Control and Prevention (CDC).

This indicator provides information about the rate of persons living with HIV (persons per 100,000 population).Human immunodeficiency virus (HIV) infection remains a significant public health concern, with more than 59,000 Los Angeles County residents estimated to be currently living with HIV. Certain communities, such as low-income communities, communities of color, and sexual and gender minority communities, bear a disproportionate burden of this epidemic. The Ending the HIV Epidemic national initiative strives to eliminate the US HIV epidemic by 2030, focusing on four key strategies: Diagnose, Treat, Prevent, and Respond. Achieving this goal requires a collaborative effort involving cities, community organizations, faith-based institutions, healthcare professionals, and businesses. Together, they can create an environment that promotes prevention, reduces stigma, and empowers individuals to safeguard themselves and their partners from HIV. Stakeholders can advance health equity by focusing on the most affected communities and sub-populations.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

BackgroundWashington DC has a high burden of HIV with a 2.0% HIV prevalence. The city is a national and international hub potentially containing a broad diversity of HIV variants; yet few sequences from DC are available on GenBank to assess the evolutionary history of HIV in the US capital. Towards this general goal, here we analyze extensive sequence data and investigate HIV diversity, phylodynamics, and drug resistant mutations (DRM) in DC.MethodsMolecular HIV-1 sequences were collected from participants infected through 2015 as part of the DC Cohort, a longitudinal observational study of HIV+ patients receiving care at 13 DC clinics. Sequences were paired with Cohort demographic, risk, and clinical data and analyzed using maximum likelihood, Bayesian and coalescent approaches of phylogenetic, network and population genetic inference. We analyzed 601 sequences from 223 participants for int (~864 bp) and 2,810 sequences from 1,659 participants for PR/RT (~1497 bp).ResultsNinety-nine and 94% of the int and PR/RT sequences, respectively, were identified as subtype B, with 14 non-B subtypes also detected. Phylodynamic analyses of US born infected individuals showed that HIV population size varied little over time with no significant decline in diversity. Phylogenetic analyses grouped 13.5% of the int sequences into 14 clusters of 2 or 3 sequences, and 39.0% of the PR/RT sequences into 203 clusters of 2–32 sequences. Network analyses grouped 3.6% of the int sequences into 4 clusters of 2 sequences, and 10.6% of the PR/RT sequences into 76 clusters of 2–7 sequences. All network clusters were detected in our phylogenetic analyses. Higher proportions of clustered sequences were found in zip codes where HIV prevalence is highest (r = 0.607; P<0.00001). We detected a high prevalence of DRM for both int (17.1%) and PR/RT (39.1%), but only 8 int and 12 PR/RT amino acids were identified as under adaptive selection. We observed a significant (P<0.0001) association between main risk factors (men who have sex with men and heterosexuals) and genotypes in the five well-supported clusters with sufficient sample size for testing.DiscussionPairing molecular data with clinical and demographic data provided novel insights into HIV population dynamics in Washington, DC. Identification of populations and geographic locations where clustering occurs can inform and complement active surveillance efforts to interrupt HIV transmission.

This was a retrospective unmatched case control study, which targeted 583 (147 cases and 436 controls) HIV infected individuals attending HIV clinics at eleven USAID/SUSTAIN supported Ugandan RRH. The specific objectives were 1. To identify the foods commonly consumed by PLHIV attending HIV clinics at RRH in Uganda. 2. To compare dietary patterns of malnourished and non-malnourished HIV patients attending HIV clinics at RRH in Uganda. 3. To explore demographic, socio-economic and hospital care factors associated with dietary patterns among HIV patients attending HIV clinics at RRH in Uganda. 4. To identify and compare coping mechanisms during food scarcity between the malnourished and non-malnourished HIV patients attending HIV clinics at RRH in Uganda.

United States US: Children: 0-14 Living with HIV data was reported at 2,500.000 Person in 2019. This records a decrease from the previous number of 2,800.000 Person for 2018. United States US: Children: 0-14 Living with HIV data is updated yearly, averaging 3,700.000 Person from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 4,700.000 Person in 2010 and a record low of 2,500.000 Person in 2019. United States US: Children: 0-14 Living with HIV data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Children living with HIV refers to the number of children ages 0-14 who are infected with HIV.;UNAIDS estimates.;;

BackgroundIn 2015, there were approximately 40,000 new HIV diagnoses in the United States. Pre-exposure prophylaxis (PrEP) is an effective strategy that reduces the risk of HIV acquisition; however, uptake among those who can benefit from it has lagged. In this study, we 1) compared the characteristics of patients who were prescribed PrEP with individuals newly diagnosed with HIV infection, 2) identified the specialties of practitioners prescribing PrEP, 3) identified metropolitan statistical areas (MSAs) within the US where there is relatively low uptake of PrEP, and 4) reported median amounts paid by patients and third-party payors for PrEP.Methods and findingsWe analyzed prescription drug claims for individuals prescribed PrEP in the Integrated Dataverse (IDV) from Symphony Health for the period of September 2015 to August 2016 to describe PrEP patients, prescribers, relative uptake, and payment methods in the US. Data were available for 75,839 individuals prescribed PrEP, and findings were extrapolated to approximately 101,000 individuals, which is less than 10% of the 1.1 million adults for whom PrEP was indicated. Compared to individuals with newly diagnosed HIV infection, PrEP patients were more likely to be non-Hispanic white (45% versus 26.2%), older (25% versus 19% at ages 35–44), male (94% versus 81%), and not reside in the South (30% versus 52% reside in the South).Using a ratio of the number of PrEP patients within an MSA to the number of newly diagnosed individuals with HIV infection, we found MSAs with relatively low uptake of PrEP were concentrated in the South. Of the approximately 24,000 providers who prescribed PrEP, two-thirds reported primary care as their specialty. Compared to the types of payment methods that people living with diagnosed HIV (PLWH) used to pay for their antiretroviral treatment in 2015 to 2016 reported in the Centers for Disease Control and Prevention (CDC) HIV Surveillance Special Report, PrEP patients were more likely to have used commercial health insurance (80% versus 35%) and less likely to have used public healthcare coverage or a publicly sponsored assistance program to pay for PrEP (12% versus 45% for Medicaid). Third-party payors covered 95% of the costs of PrEP. Overall, we estimated the median annual per patient out-of-pocket spending on PrEP was approximately US$72. Limitations of this study include missing information on prescription claims of patients not included in the database, and for those included, some patients were missing information on patient diagnosis, race/ethnicity, educational attainment, and income (34%–36%).ConclusionsOur findings indicate that in 2015–2016, many individuals in the US who could benefit from being on PrEP were not receiving this HIV prevention medication, and those prescribed PrEP had a significantly different distribution of characteristics from the broader population that is at risk for acquiring HIV. PrEP patients were more likely to pay for PrEP using commercial or private insurance, whereas PLWH were more likely to pay for their antiretroviral treatment using publicly sponsored programs. Addressing the affordability of PrEP and otherwise promoting its use among those with indications for PrEP represents an important opportunity to help end the HIV epidemic.

Age-sex Specific Incidence Rates for HIV for Alberta expressed as per 100,000 population.

United States US: Newly Infected with HIV: Adults: Aged 15-49 data was reported at 27,000.000 Number in 2021. This records a decrease from the previous number of 28,000.000 Number for 2020. United States US: Newly Infected with HIV: Adults: Aged 15-49 data is updated yearly, averaging 32,000.000 Number from Dec 2010 (Median) to 2021, with 12 observations. The data reached an all-time high of 34,000.000 Number in 2010 and a record low of 27,000.000 Number in 2021. United States US: Newly Infected with HIV: Adults: Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of adults (ages 15-49) newly infected with HIV.;UNAIDS estimates.;;This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

aMajor mutations associated with resistance to INSTI as described [71], [86]. INSTI-resistance mutations identified using deep sequencing but not by population sequencing are indicated in bold.

The Malawi Population-Based HIV Impact Assessment (MPHIA), a household-based national survey, was conducted between November 2015 and August 2016 in order to measure the status of Malawi’s national HIV response. MPHIA offered HIV counseling and testing with return of results, and collected information about uptake of care and treatment services. This survey is the first in Malawi to measure national HIV incidence, pediatric HIV prevalence, and viral load suppression. The results provide information on national and subnational progress toward control of the HIV epidemic. MPHIA was led by the Government of Malawi through the Ministry of Health (MOH), conducted with funding from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and technical assistance through the U.S. Centers for Disease Control and Prevention (CDC). The survey was implemented by ICAP at Columbia University in collaboration with local partners, including the Centre for Social Research (CSR) at the University of Malawi, the National Statistics Office (NSO), and the College of Medicine-Johns Hopkins Project (COM-JHP) at the University of Malawi.

Although HIV caused one of the worst epidemics since the late twentieth century, China and the U.S. has made substantial progress to control the spread of HIV/AIDS. However, the trends of HIV/AIDS incidence remain unclear in both countries. Therefore, this study aimed to highlight the long-term trends of HIV/AIDS incidence by gender in China and the U.S. population. The data were retrieved from the Global Burden of Disease (GBD) database since it would be helpful to assess the impact/role of designed policies in the control of HIV/AIDS incidence in both countries. The age-period-cohort (APC) model and join-point regression analysis were employed to estimate the age-period-cohort effect and the average annual percentage change (AAPC) on HIV incidence. Between 1994 and 2019, we observed an oscillating trend of the age-standardized incidence rate (ASIR) in China and an increasing ASIR trend in the U.S. Despite the period effect in China declined for both genders after peaked in 2004, the age effect in China grew among the young (from 15–19 to 25–29) and the old age groups (from 65–69 to 75–79). Similarly, the cohort effect increased among those born in the early (from 1924–1928 to 1934–1938) and the latest birth groups (from 1979–1983 to 2004–2009). In the case of the U.S., the age effect declined after it peaked in the 25–29 age group. People born in recent birth groups had a higher cohort effect than those born in early groups. In both countries, women were less infected by HIV than men. Therefore, besides effective strategies and awareness essential to protect the young age groups from HIV risk factors, the Chinese government should pay attention to the elderly who lacked family support and were exposed to HIV risk factors.

United States US: Newly Infected with HIV: Children: Aged 0-14 data was reported at 200.000 Number in 2019. This stayed constant from the previous number of 200.000 Number for 2018. United States US: Newly Infected with HIV: Children: Aged 0-14 data is updated yearly, averaging 200.000 Number from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 500.000 Number in 2012 and a record low of 200.000 Number in 2019. United States US: Newly Infected with HIV: Children: Aged 0-14 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of children (ages 0-14) newly infected with HIV.;UNAIDS estimates.;;This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

aMajor mutations associated with resistance to INSTI as described [71], [86].bPlasma viral load (log10 copies/ml). INSTI-R, mutations associated with resistance to INSTI; PI (1), number of primary mutations associated with resistance to PI; PI (2), number of secondary mutations associated with resistance to PI; #TAMs, number of thymidine analogue-associated mutations; #NAMs, number of nucleoside analogue-associated mutations; NNRTI (1), number of primary mutations associated with resistance to NNRTI. EC50 FC, based on VIRALARTS [49] three independent EC50 replicates for each drug were used to calculate the fold changes (FC) of the query viruses relative to the HIV-1NL4-3 control and the mean EC50 FC is indicated. MAX, complete virus inhibition was not achieved using the maximum drug concentration, i.e., virus was completely resistant to the respective antiretroviral drug. Virus 08-175 contained the INSTI-resistance mutations T66A and S147G.

BackgroundConventional epidemiological surveillance of infectious diseases is focused on characterization of incident infections and estimation of the number of prevalent infections. Advances in methods for the analysis of the population-level genetic variation of viruses can potentially provide information about donors, not just recipients, of infection. Genetic sequences from many viruses are increasingly abundant, especially HIV, which is routinely sequenced for surveillance of drug resistance mutations. We conducted a phylodynamic analysis of HIV genetic sequence data and surveillance data from a US population of men who have sex with men (MSM) and estimated incidence and transmission rates by stage of infection.Methods and FindingsWe analyzed 662 HIV-1 subtype B sequences collected between October 14, 2004, and February 24, 2012, from MSM in the Detroit metropolitan area, Michigan. These sequences were cross-referenced with a database of 30,200 patients diagnosed with HIV infection in the state of Michigan, which includes clinical information that is informative about the recency of infection at the time of diagnosis. These data were analyzed using recently developed population genetic methods that have enabled the estimation of transmission rates from the population-level genetic diversity of the virus. We found that genetic data are highly informative about HIV donors in ways that standard surveillance data are not. Genetic data are especially informative about the stage of infection of donors at the point of transmission. We estimate that 44.7% (95% CI, 42.2%–46.4%) of transmissions occur during the first year of infection.ConclusionsIn this study, almost half of transmissions occurred within the first year of HIV infection in MSM. Our conclusions may be sensitive to un-modeled intra-host evolutionary dynamics, un-modeled sexual risk behavior, and uncertainty in the stage of infected hosts at the time of sampling. The intensity of transmission during early infection may have significance for public health interventions based on early treatment of newly diagnosed individuals.Please see later in the article for the Editors' Summary

The Online Tuberculosis Information System (OTIS) on CDC WONDER contains information on verified tuberculosis (TB) cases reported to the Centers for Disease Control and Prevention (CDC) by state health departments, the District of Columbia and Puerto Rico since 1993. These data were extracted from the CDC national TB surveillance system. OTIS reports case counts, incidence rates, population counts, percentage of cases that completed therapy within 1 year of diagnosis, and percentage of cases tested for drug susceptibility. Data for 22 variables are included in the data set, including: age groups, race / ethnicity, sex, vital status, year reported, state, metropolitan area, several patient risk factors, directly observed therapy, disease verification criteria and multi-drug resistant TB. Each year these data are updated with an additional year of cases plus revisions to cases reported in previous years. OTIS is produced by the U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, viral Hepatitis, STD and TB Prevention (NCHHSTP).

The 2011 Uganda AIDS Indicator Survey (AIS) is a nationally representative, population-based, HIV serological survey. The survey was designed to obtain national and sub-national estimates of the prevalence of HIV and syphilis infection as well as information about other indicators of programme coverage, such as knowledge, attitudes, and sexual behaviour related to HIV/AIDS. Data collection took place from 8 February to the first few days of September 2011. The UAIS was implemented by the Ministry of Health. ICF International provided financial and technical assistance for the survey through a contract with USAID/Uganda. Financial and technical assistance was also provided by the U.S. Centers for Disease Control and Prevention (CDC). Financial support was provided by the Government of Uganda, the U.S. Agency for International Development (USAID), the President’s Emergency Fund for AIDS Relief (PEPFAR), the World Health Organisation (WHO), the UK Department for International Development (DFID), and the Danish International Development Agency (DANIDA) through the Partnership Fund. The Uganda Bureau of Statistics also partnered in the implementation of the survey. Central testing was conducted at the Uganda Virus Research Institute, with CDC conducting CD4 counts, polymerase chain reaction (PCR) testing for children, and quality control tests. The survey provided information on knowledge, attitudes, and behaviour regarding HIV/AIDS and indicators of coverage and access to other programmes, for example, HIV testing, access to antiretroviral therapy, services for treating sexually transmitted infections, and coverage of interventions to prevent motherto-child transmission of HIV. The survey also collected information on the prevalence of HIV and syphilis and their social and demographic variations in the country. The overall goal of the survey was to provide programme managers and policymakers involved in HIV/AIDS programmes with strategic information to effectively plan, implement, and evaluate HIV/AIDS interventions. The information obtained from the survey will help programme implementers to monitor and evaluate existing programmes and design new strategies for combating the HIV/AIDS epidemic in Uganda. The survey data will in addition be used to make population projections and to calculate indicators developed by the UN General Assembly Special Session (UNGASS), USAID, PEPFAR, the UNAIDS Programme, WHO, the Uganda Health Sector Strategic and Investment Plan, and the Uganda AIDS Commission. The specific objectives of the 2011 UAIS were to provide information on: • Prevalence and distribution of HIV and syphilis • Indicators of knowledge, attitudes, and behaviour related to HIV/AIDS and other sexually transmitted infections • HIV/AIDS programme coverage indicators • Levels of CD4 T-lymphocyte counts among HIV-positive adults to quantify HIV treatment needs and to calibrate model-based estimates • HIV prevalence that can be used to calibrate and improve the sentinel surveillance system • Risk factors for HIV and syphilis infections in Uganda.